News

4th round of financing for VitaDX

21 September 2020 -

VitaDX completes a €3M financing round with its historical investors GO CAPITAL, ODYSSEE Venture and FFBB Management and its financial partners…

CE marking of the VisioCyt® solution

11 February 2020 -

News

VitaDX is very proud to announce the CE marking of its first software solution dedicated to bladder cancer diagnosis: VisioCyt®.

VitaDX, Go Capital, Odyssee Venture et Auriga

VitaDX raises €4 million from GO CAPITAL, AURIGA Partners, ODYSSEE Venture and FFBB Management

9 July 2019 -

News

This fundraising will allow VitaDX to finalize the development and ensure the commercial deployment of its first early bladder cancer detection…

UC3: VitaDX, Cerballiance Finistère and the COSS laboratory are collaborating within the framework of the "Collaborative innovation at the crossroads of different sectors" initiative.

14 May 2019 -

Publishing

The Characterisation of Urothelial Cancer Cells "UC3" project funded by the Brittany region, Rennes Métropole and the ERDF aims to deepen our…

”Paroles d’Experts” show by La Tribune

16 July 2018 -

News

Allan Rodriguez (CEO and co-founder of VitaDX) and Pascal Eschwège (Professor of Urology at the University Hospital of Nancy and co-founder of…

DeepTech4Good Paris

12 July 2018 -

News

VitaDX is very happy to be a Health & Wellness Laureate at DeepTech4Good !

REALIZE AstraZeneca

11 July 2018 -

News

VitaDX is very pleased to be part of the 5 Therapeutic Innovation Startups selected by AstraZeneca to be part of the support program REALIZE!

Against cancer VitaDX invests 5 years of efforts.

31 May 2018 -

Conventions

Five years of efforts to transform a patented technology into an industrialised solution, tested and certified.

Artificial intelligence. Healthcare and patients have everything to gain from the digital era – Le Télégramme

15 May 2018 -

Conventions

VitaDX citée dans Le Télégramme à l'occasion de la journée Numérique & Santé.

4th round of financing for VitaDX

21 September 2020 -

News

VitaDX completes a €3M financing round with its historical investors GO CAPITAL, ODYSSEE Venture and FFBB Management and its financial partners…

CE marking of the VisioCyt® solution

11 February 2020 -

News

VitaDX is very proud to announce the CE marking of its first software solution dedicated to bladder cancer diagnosis: VisioCyt®.

VitaDX raises €4 million from GO CAPITAL, AURIGA Partners, ODYSSEE Venture and FFBB Management

9 July 2019 -

News

This fundraising will allow VitaDX to finalize the development and ensure the commercial deployment of its first early bladder cancer detection…

UC3: VitaDX, Cerballiance Finistère and the COSS laboratory are collaborating within the framework of the "Collaborative innovation at the crossroads of different sectors" initiative.

14 May 2019 -

Publishing

The Characterisation of Urothelial Cancer Cells "UC3" project funded by the Brittany region, Rennes Métropole and the ERDF aims to deepen our…

”Paroles d’Experts” show by La Tribune

16 July 2018 -

News

Allan Rodriguez (CEO and co-founder of VitaDX) and Pascal Eschwège (Professor of Urology at the University Hospital of Nancy and co-founder of…

DeepTech4Good Paris

12 July 2018 -

News

VitaDX is very happy to be a Health & Wellness Laureate at DeepTech4Good !

REALIZE AstraZeneca

11 July 2018 -

News

VitaDX is very pleased to be part of the 5 Therapeutic Innovation Startups selected by AstraZeneca to be part of the support program REALIZE!

Against cancer VitaDX invests 5 years of efforts.

31 May 2018 -

Conventions

Five years of efforts to transform a patented technology into an industrialised solution, tested and certified.

Artificial intelligence. Healthcare and patients have everything to gain from the digital era – Le Télégramme

15 May 2018 -

Conventions

VitaDX citée dans Le Télégramme à l'occasion de la journée Numérique & Santé.